CSPC Innovation Pharma continues cash management with new investments

CSPC Innovation Pharmaceutical announced the progress of its cash management strategy, utilizing idle raised funds as approved by its shareholders. The company's board and supervisory board, along with the 2024 annual general meeting, approved the use of up to RMB 800 million in idle raised funds and RMB 800 million in自有 funds for cash management, investing in principal-protected products with high safety and liquidity. This strategy aims to enhance capital efficiency without impacting ongoing project construction or operations.

As of the announcement date, the company has a total of RMB 40,500,000 in outstanding idle raised funds under cash management. The announcement detailed one product that matured recently: a RMB 10,000,000 "2025 Hooked-rate Public Structured Deposit Customized Ninth Period Product 28" from China Everbright Bank, which commenced on September 3, 2025, matured on December 3, 2025, and yielded a return of RMB 41.25.

Additionally, the company initiated a new cash management product: a RMB 10,000,000 "2025 Hooked-rate Public Structured Deposit Customized Twelfth Period Product 113" with China Everbright Bank. This product, starting on December 5, 2025, and maturing on March 5, 2026, offers a principal-protected floating income with an expected annualized yield of 1%/1.6%/1.7%. The company assures that its cash management activities adhere to strict risk control measures, including careful selection of investment products and continuous monitoring of market conditions.